TEMPORARY BALLOON OCCLUSION OF SUBCLAVIAN VEIN IN ITS INJURY DURING TRANSVENOUS LEADS EXTRACTION IN PATIENT WITH A SUPERIOR VENA CAVA SYNDROME: CASE REPORT

S.A.Aivazian, I.N.Sorokin, V.A.Belskiy
Federal Budget Institution of Health Volga reginal medical center Federal Bio-Medical Agency, Russia, Nizhniy Novgorod, 2 Niznevolzhskaya emb.

In this article we have described clinical case of successful balloon catheter for peripheral angioplasty usage for occlusion of subclavian vein which was damaged during transvenous lead extraction of old leads. It helped to prevent life-threatening bleeding.

Key words: transvenous lead extraction; superior vena cava syndrome; permanent pacemaker; bleeding

Conflict of Interests: none
Funding: none
Received: 20.11.2021 Revision received: 31.12.2021 Accepted: 03.01.2022
Corresponding author: Sergei Aivazian, E-mail: sergei_aivazyan@mail.ru

S.A.Aivazian - ORCID ID 0000-0002-9642-9754, I.N.Sorokin - ORCID ID 0000-0002-7350-8353, V.A.Belskiy - ORCID ID 0000-0002-6135-5441

For citation: Aivazian SA, Sorokin IN, Belskiy VA. Temporary balloon occlusion of subclavian vein in its injury during transvenous leads extraction in patient with a superior vena cava syndrome: case report. Journal of Arrhythmology. 2022;29(1): 58-62. https://doi.org/10.35336/V A-2022-1-09.

Patients with implanted electronic cardiac devices frequently experience infectious complications, which can be life-threatening if sepsis and infective endocarditis develop [1, 2]. Complete removal of the pacing system with transvenous lead extraction (TLE) appears to be the treatment of choice in most cases of device infection [3].

Myocardial damage and hemopericardium with cardiopulmonary arrest constitute the most common complications of TLE [4]. Vein injury is a rare complication of TLE. It occurs in 0.16-0.41% of extractions [5]. Superior vena cava (SVC) injury poses the highest risk. The mortality rate for this dangerous complication can exceed 50% [6]. A Bridge balloon (Philips, Netherlands) has been proposed for temporary hemostasis of SVC (not registered in the Russian Federation) [7]. However, subclavian and axillary veins injury often related with major bleeding. Manual compression for hemostasis may be ineffective, whereas surgical reconstruction of the subclavian vein is technically challenging and may be associated with major bleeding and blood loss.

We are aware of only one clinical case in which a balloon was used to stop bleeding from a subclavian vein injury during TLE [8]. In this particular clinical case in a patient with SVC syndrome, we also performed temporary hemostasis from an injured subclavian/axillary vein with a balloon.

The patient is a 35-year-old woman with a body mass index of 18.6 kg/m2. Due to congenital complete atrioventricular block, she was implanted with a Relay dual-chamber pacemaker with passively fixed leads (Intermedics, USA) in 1998, when she was 11 years old. The pacemaker pocket was formed in the left subclavian region. The ventricular lead was fixed at the apex of the right ventricle, and the atrial lead was fixed at the appendage of the right atrium. The pacemaker was subsequently replaced twice (2010, 2017) preserving initial leads. In 2018, the patient experienced an unmedicated vaginal delivery and breastfed her child for three years. The woman noted that there was traumatization of the pacemaker pocket area when feeding the child and decanting milk. In 2021, the patient noticed skin darkening in the pacemaker pocket area and subsequently devel-
oped a skin defect with cloudy discharge through which a foreign body was visually identified. No fever was observed in the patient.

Face and eyelids swelling was revealed during the first examination. When a more detailed history was taken, the patient reported that the face and upper extremities swelling had developed about two years ago. Enlarged veins are observed on the anterior and lateral surfaces of the chest. A 2x1 cm skin defect with a small amount of mucopurulent discharge is observed in the area of the pacemaker pocket. A section of the lead can be seen through the skin defect (Figure 1). No abnormal pacing is noted on analysis of the ECG data and during device interrogation. Lead-associated endocarditis ruled out by transoesophageal echocardiography (Echo): the heart valves are not altered, no vegetation are present. Haemoglobin on admission was 120 g/l. No inflammatory markers are detected in the blood. It was decided to completely remove the pacing system with TLE and implant a new system on the right side. The EROS and SAFeTY TLE scales define the risk of extraction as high [9, 10].

Operation description

The operation was performed in a hybrid operating room by a cardiovascular surgeon together with a specialist in endovascular diagnosis and treatment under complete intravenous anaesthesia with mechanical ventilation. Invasive blood pressure monitoring via the radial artery was performed. A Prelude 6Fr haemostatic introducer (Merit Medical Systems, USA) was inserted into the right internal jugular vein. Phlebography was performed through the introducer. SVC stenosis greater than 20 mm in length and over 90-95% in diameter was noted at the junction of the vein with the right atrium with the formation of collaterals and overflow into the inferior vena cava via the non-compartmental vein (Figure 2). For diagnostic purposes, a 145 cm Roadrunner PC.035 hydrophilic guidewire (Cook, USA) was inserted into the SVC through the introducer set. The lead was placed behind the stenosis in the right atrium. The possibility of implanting new leads on the right side was thereby determined. The right femoral vein was catheterized with a double lumen infusion catheter, and a Prelude 6Fr introducer (Merit Medical Systems, USA) was inserted into the right femoral vein through which a temporary pacing lead was inserted into the right ventricle. A Radifocus 10Fr introducer (Terumo, Japan) was inserted into the left femoral vein through which an AcuNav 8Fr transducer (Siemens, Germany) was passed for intracardiac echocardiography.

The surgical field was treated for the subsequent sternotomy. The skin defect was dissected, and the pacemaker and leads were isolated from the scar tissue using a monopolar coagulator. The mucous secretion from the pocket was collected for culturing and determining the sensitivity of the flora to antibiotics. The fibrous capsule of the pocket was removed with a coagulator. The leads were exposed through a separate incision in the left subclavian region. It was not possible to locate the fixation sleeves. In the search for fixation sleeves, the atrial lead was isolated at the entrance to the subclavian vein, and the ventricular lead was isolated at the entrance to the axillary vein. After cutting off the connector part of the leads, the LLD EZ stilettos (Spectranetics, USA) were inserted. The atrial lead was removed using a TightRail 11Fr device (Spectranetics, USA). The section of the SVC around the stenosis was calcified (Figure 3), which caused difficulty in

Fig. 2. Phlebography: narrowing of the superior vena cava at its junction with the right atrium (extensive collateral network).

Fig. 3. Removed leads showing areas of calcified fibrous capsule.

Fig. 4. Balloon catheter inflated in the left subclavian vein: a) chest radiograph, b) photograph of the surgical phase.
A new Estella DR -T dual chamber pacemaker (Biotronik, Germany) was implanted on the right side against the background of temporary pacing. A new pacemaker pocket was formed under the right pectoralis major muscle. The right axillary vein was punctured twice and 145 cm long Roadrunner PC.035 hydrophilic guidewires (Cook, USA) were passed behind the subtotal SVC stenosis and into the right atrium and further into the inferior vena cava. A 25 cm Radifocus 7 Fr (Terumo, Japan) introducer was placed along the leads, through which ventricular and atrial leads were positioned with active fixation were positioned with satisfactory pacing parameters (Figure 5). In the postoperative period, hemodynamics remained stable. Blood tests showed a decrease in haemoglobin to 88 g/l and no haemotransfusions were performed. The wounds healed with primary tension.

**DISCUSSION**

Subclavian or axillary veins injury with major bleeding is a rare complication of TLE. In this case, we mistakenly inserted a rotary dilator (11Fr), which is essentially a mechanically driven cutting tool, without proper visual inspection after visualizing the exposed axillary/clavicular vein (usually no vein is visualized in scar tissue in TLE), and thereby significantly damaged the anterior wall of the vein. The injury may also have been induced by the fact that the entry point of the ventricular lead into the vein was calcified (see Figure 3). Calcification of the fibrous capsule of the leads presents a typical situation in patients whose leads are more than 15 years old and who were implanted in childhood or at a young age. It is recognized that the time the leads remain in the body is a significant risk factor for extraction on the EROS and SAFeTY scores. In our opinion, to prevent this complication, the vein entry should be performed with close preliminary visual inspection using a SightRail Telescope propylene dilator (Spectranetics, USA) and preceded by a double cicatricial suture around the lead. A stenosis of the superior vena cava of more than 90% and the resulting venous hypertension also contributed to severe bleeding.

New device implantation after infected system removal is a significant problem, especially in patients with venous access issues. The methods to solve this problem are the following: epicardial implantation of the system, implantation through the iliac/femoral vein, recanalization and endovascular plastic surgery of the occluded/stenotic vein. Leadless pacemaker (not registered in the Russian Federation) may be considered in the future in a small group of patients with infectious complications of pacemaker and SVC occlusion [11,12].

According to current guidelines, implantation of a leadless pacemaker is recommended in the absence of venous access to the SVC or the presence of the high risk of device infection (history of infectious complications, haemodialysis patient) [13].

In this clinical situation, we believe that a leadless pacemaker is not recommended for several reasons: 1) the patient is indicated for implantation in the DDD mode; 2) the patient has a low risk of reinfection of the...
pacing system; 3) implantation of this device is not recommended in young patients with a life expectancy of more than 20 years [13].

We opted for endocardial lead implantation via long introducer through the stenosis of the superior vena cava as the most feasible, easiest, and least traumatic option. Modern surgical rooms in which cardiac electronic devices implanted and TLE performed are should include hydrophilic leads 140-200 cm long, introducers 23-25 cm long and balloon catheters. In some cases, a multidisciplinary approach needs to be considered in the management of patients with complications following electronic cardiac device implantation. In our case, temporary occlusion of the vein with a balloon catheter prevented life-threatening bleeding and we were able to suture the vein defect.

REFERENCES

1. Han HC, Hawkins NM, Pearman CM, et al. Epidemiology of cardiac implantable electronic device infections: incidence and risk factors. Europace. 2021;23(23 Suppl 4): iv3-iv10. https://doi.org/10.1093/europace/eua042.

2. Johansen JB, Jorgensen D, Moller M, et al. Infection after pacemaker implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299 consecutive patients. Eur Heart J. 2011;32: 991-998. https://doi.org/10.1093/eurheartj/ehq497.

3. Blomström-Lundqvist C, Traykov V, Erba PA, et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (IS-CVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Europace. 2020;22(4): v515-549. https://doi.org/10.1093/europace/euz246.

4. Sapelnikov OV. Complication of lead extraction. In. Cardiac implantable electronic device lead extraction: indications, methods, equipment, patient management (Ed. Revishvili AS). Moscow 2021: 103-109. (In Russ). ISBN 978-5-88429-268-0.

5. Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017;14(12): e503-e551. https://doi.org/10.1016/j.hrthm.2017.09.001.

6. Bongiorni MG, Burri H, Deharo JC, et al. 2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/LAHRS. Europace. 2018;00: 1-11. https://doi.org/10.1093/europace/euy050.

7. Azarrafiiy R, Tsang DC, Wilkoff BL, et al. Endovascular Occlusion Balloon for treatment of superior vena cava tears during transvenous lead extraction. A multi-year analysis and an update to best practice protocol. Circ Arrhythm Electrophysiol. 2019;12. https://doi.org/10.1161/CIRCEP.119.007266.

8. Bhullar A, Alcantara S, Yu PJ, et al. It works there too! Use of the endovascular occlusion balloon to rescue left subclavian vein injury during lead extraction. Heart Rhythm Case Rep. 2021;7(6): 395-397. https://doi.org/10.1016/j.hrcr.2021.03.012.

9. Sidhu BS, Ayis S, Gould J, et al. ELECTRa Investigators Group. Risk stratification of patients undergoing transvenous lead extraction with the ELECTRa Registry Outcome Score (EROS): An ESC EHRA EORP European lead extraction ConTRolled, E.L.ECTRa registry analysis. Europace. 2021: euab037. https://doi.org/10.1093/europace/euab037.

10. Jacheć W, Polewczyk A, Polewczyk M, et al. Transvenous Lead Extraction SAFETY Score for Risk Stratification and Proper Patient Selection for Removal Procedures Using Mechanical Tools. J Clin Med. 2020;9: 361. https://doi.org/10.3390/jcm9020361.

11. Abdarakhmanov AS, Pya YuV, Alimbaev SA, et al. Implantation of electrodeless pacemaker after removal of infected electrodes. Journal of Arrhythmology. 2018;(91): 57-59. (In Russ.)

12. El-Chami MF, Johansen JB, Zaidi A, et al. Leadless pacemaker implant in patients with pre-existing infections: results from the Micra postapproval registry. J Cardiovasc Electrophysiol 2019;30(4): 569-574. http://doi.org/10.1111/jce.13851.

13. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy Eur Heart J. 2021;42(35):3427-3520. http://doi.org/10.1093/eurheartj/ehab364.